{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:47:44Z","timestamp":1794505664153,"version":"4.9.1"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011946","name":"Abbott Diabetes Care","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100011946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Identify non-glycemic factors affecting the relationship between fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c), in order to refine diabetes diagnostic criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research design and methods<\/jats:title>\n                  <jats:p>Relationship between FPG\u2013HbA1c was assessed in 12\u2009531 individuals from 2001 to 2018 US National Health and Nutrition Examination Survey. Using a recently described method, FPG and HbA1c were used to calculate apparent glycation ratio (AGR) of red blood cells for different subgroups based on age, race, and gender.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At an FPG of 7\u2009mmol\/L, black individuals had a higher HbA1c (p&lt;0.001, mean: 50.2\u2009mmol\/mol, 95%\u2009CI (49.8 to 50.4)) compared with white individuals (47.4\u2009mmol\/mol (47.2 to 47.5)). This corresponds to NGSP (National Glycohemoglobin Standardization Program) units of 6.7% and 6.5% for black versus white individuals, respectively. Similarly, individuals under 21 years had lower HbA1c (p&lt;0.001, 47.9\u2009mmol\/mol (47.7 to 48.1), 6.5%) compared with those over 50 years (48.3\u2009mmol\/mol (48.2 to 48.5), 6.6%). Differences were also observed between women (p&lt;0.001, 49.2\u2009mmol\/mol (49.1 to 49.3), 6.7%) and men (47.0\u2009mmol\/mol (46.8 to 47.1), 6.5%). Of note, the difference in HbA1c at FPG of 7\u2009mmol\/L in black females over 50 and white males under 21 years was 5\u2009mmol\/mol (0.46%). AGR differences according to race (p&lt;0.001), age (p&lt;0.001), and gender (p&lt;0.001) explained altered glucose\u2013HbA1c relationship in the analyzed groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>FPG\u2013HbA1c relationship is affected by non-glycemic factors leading to incorrect diagnosis of diabetes in some individuals and ethnic groups. Assessment of AGR helps understand individual-specific relationship between glucose levels and HbA1c, which has the potential to more accurately diagnose and manage diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2023-003470","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:01:12Z","timestamp":1709596872000},"page":"e003470","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Variation in the relationship between fasting glucose and HbA1c: implications for the diagnosis of diabetes in different age and ethnic groups"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-0029","authenticated-orcid":false,"given":"Yashesvini","family":"Ram","sequence":"first","affiliation":[{"name":"Clinical Affairs, Abbott Diabetes Care, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjin","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Affairs, Abbott Diabetes Care, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-4751","authenticated-orcid":false,"given":"Alan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Clinical Affairs, Abbott Diabetes Care, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Dunn","sequence":"additional","affiliation":[{"name":"Clinical Affairs, Abbott Diabetes Care, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi A","family":"Ajjan","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"2025073112303331000_12.2.e003470.1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association . Glycemic targets: standards of medical care in diabetes 2022. Diabetes Care 2021;45.","DOI":"10.2337\/dc22-Sint"},{"key":"2025073112303331000_12.2.e003470.2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1227"},{"key":"2025073112303331000_12.2.e003470.3","doi-asserted-by":"crossref","DOI":"10.5888\/pcd18.200365","article-title":"Hba 1C performance in African descent populations in the United States with normal glucose tolerance, prediabetes, or diabetes: a scoping review","volume":"18","author":"Khosla","year":"2021","journal-title":"Prev Chronic Dis"},{"key":"2025073112303331000_12.2.e003470.4","doi-asserted-by":"publisher","DOI":"10.4158\/EP10119.OR"},{"key":"2025073112303331000_12.2.e003470.5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08841209"},{"key":"2025073112303331000_12.2.e003470.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2016-000213","article-title":"Do Glycemic marker levels vary by race? differing results from a cross-sectional analysis of individuals with and without diagnosed diabetes","volume":"4","author":"Carson","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025073112303331000_12.2.e003470.7","first-page":"328","article-title":"Genetic ancestry markers and difference in A1C between African American and white in the diabetes prevention program","volume":"104","author":"Hivert","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025073112303331000_12.2.e003470.8","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s00125-014-3301-1","article-title":"Association of African genetic ancestry with fasting glucose and Hba 1C levels in non-diabetic individuals: the Boston area community health (BACH) Prediabetes study","volume":"57","author":"Meigs","year":"2014","journal-title":"Diabetologia"},{"key":"2025073112303331000_12.2.e003470.9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/M16-2596","article-title":"Racial differences in the relationship of glucose concentrations and hemoglobin A1C levels","volume":"167","author":"Bergenstal","year":"2017","journal-title":"Ann Intern Med"},{"key":"2025073112303331000_12.2.e003470.10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/bjhp.12120","article-title":"Financial strain, inflammatory factors, and Haemoglobin A 1C levels in African American women","volume":"20","author":"Cutrona","year":"2015","journal-title":"Br J Health Psychol"},{"key":"2025073112303331000_12.2.e003470.11","doi-asserted-by":"crossref","DOI":"10.5888\/pcd18.200365","article-title":"Hba1C performance in African descent populations in the United States with normal glucose tolerance, Prediabetes, or diabetes: a Scoping review","volume":"18","author":"Khosla","year":"2021","journal-title":"Prev Chronic Dis"},{"key":"2025073112303331000_12.2.e003470.12","first-page":"637","article-title":"Hba1C and age in non-diabetic subjects: an ignored Association","volume":"124","author":"Roth","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2025073112303331000_12.2.e003470.13","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1524"},{"key":"2025073112303331000_12.2.e003470.14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1932296819897613","article-title":"A kinetic model for glucose levels and hemoglobin A1C provides a novel tool for individualized diabetes management","volume":"15","author":"Xu","year":"2021","journal-title":"J Diabetes Sci Technol"},{"key":"2025073112303331000_12.2.e003470.15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1089\/dia.2020.0553","article-title":"Personal Glycation factors and calculated Hba1C for diabetes management: real-world data from the DPV Registry","volume":"23","author":"Xu","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"2025073112303331000_12.2.e003470.16","doi-asserted-by":"crossref","unstructured":"Xu Y , Hirota Y , Ajjan RA , et al . Accurate prediction of Hba1C by continuous glucose monitoring using a kinetic model with patient-specific parameters for red blood cell LifeSpan and glucose uptake. Diab Vasc Dis Res 2021;18. doi:10.1177\/14791641211013734","DOI":"10.1177\/14791641211013734"},{"key":"2025073112303331000_12.2.e003470.17","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002"},{"key":"2025073112303331000_12.2.e003470.18","unstructured":"Centers for Disease Control and Prevention (CDC) . National center for health Statistics (NCHS). National health and nutrition examination survey data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014, 2015-2016, 2017-2018. n.d. Available: https:\/\/www.cdc.gov\/nchs\/nhanes\/index.html"},{"key":"2025073112303331000_12.2.e003470.19","unstructured":"Centers for Disease Control and Prevention . National center for health Statistics (NCHS). NCHS ethics review board (ERB) approval. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, NHANES 199-2018. n.d. Available: https:\/\/www.cdc.gov\/nchs\/nhanes\/irba98.htm"},{"key":"2025073112303331000_12.2.e003470.20","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12106"},{"key":"2025073112303331000_12.2.e003470.21","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1265"},{"key":"2025073112303331000_12.2.e003470.22","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(18)52905-7"},{"key":"2025073112303331000_12.2.e003470.23","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(86)90342-1"},{"key":"2025073112303331000_12.2.e003470.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-011-0366-6"},{"key":"2025073112303331000_12.2.e003470.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2009.12.013"},{"key":"2025073112303331000_12.2.e003470.26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"The Lancet"},{"key":"2025073112303331000_12.2.e003470.27","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0573"},{"key":"2025073112303331000_12.2.e003470.28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/10408363.2018.1480591","article-title":"Hba1C method performance: the great success story of global standardization","volume":"55","author":"English","year":"2018","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2025073112303331000_12.2.e003470.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154112"},{"key":"2025073112303331000_12.2.e003470.30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01032"},{"key":"2025073112303331000_12.2.e003470.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.10.001"},{"key":"2025073112303331000_12.2.e003470.32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/dom.12449","article-title":"Gender\u2010based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient\u2010level pooled data of six randomized controlled trials","volume":"17","author":"Kautzky-Willer","year":"2015","journal-title":"Diabetes Obes Metab"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2023-003470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:30:40Z","timestamp":1753990240000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2023-003470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3,4]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bmjdrc-2023-003470"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2023-003470","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}